Literature DB >> 16863542

Risk factors for the development of esophageal adenocarcinoma in Barrett's esophagus.

Pieter J F de Jonge1, Ewout W Steyerberg, Ernst J Kuipers, Pieter Honkoop, Leonieke M M Wolters, Marjon Kerkhof, Horman van Dekken, Peter D Siersema.   

Abstract

OBJECTIVE: To identify risk factors for esophageal adenocarcinoma (EAC) in patients with Barrett's esophagus (BE).
METHODS: A hospital-based case-control study was performed in which 91 cases with EAC and 244 controls with histologically confirmed BE (>2 cm) with no dysplasia or low-grade dysplasia were included. Information on demographic, anthropometric, and lifestyle characteristics, physical activity levels, working posture, family history, gastroesophageal reflux disease (GERD) symptoms, and medication use was collected by questionnaire.
RESULTS: Cases more often were current smokers (odds ratio 3.7, 95% confidence interval 1.4-9.9), more often had a body mass index >25 assessed at age 20 (2.6, 1.2-5.5), and more frequently had been working in a stooped posture at age 20 (2.0, 1.1-3.9), compared to controls. In addition, cases less often experienced symptoms of heartburn (0.3, 0.2-0.5) and less frequently used proton pump inhibitors (0.1, 0.05-0.2), compared to controls, whereas use of nonsteroidal anti-inflammatory drugs/aspirin was more common among cases (1.8, 1.1-3.2). Cases more often were men, compared to controls (91%vs 67%, p < 0.001).
CONCLUSION: In patients with BE, the risk of EAC is related to risk factors for GERD, which is, however, asymptomatic. As these risk factors are common in Western countries, they are probably not helpful in individualization of surveillance intervals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16863542     DOI: 10.1111/j.1572-0241.2006.00626.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  28 in total

Review 1.  Risk factors for neoplastic progression in Barrett's esophagus.

Authors:  Elizabeth F Wiseman; Yeng S Ang
Journal:  World J Gastroenterol       Date:  2011-08-28       Impact factor: 5.742

2.  An Accurate Cancer Incidence in Barrett's Esophagus: A Best Estimate Using Published Data and Modeling.

Authors:  Sonja Kroep; Iris Lansdorp-Vogelaar; Joel H Rubenstein; Harry J de Koning; Reinier Meester; John M Inadomi; Marjolein van Ballegooijen
Journal:  Gastroenterology       Date:  2015-04-29       Impact factor: 22.682

3.  Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study.

Authors:  Shivaram Bhat; Helen G Coleman; Fouad Yousef; Brian T Johnston; Damian T McManus; Anna T Gavin; Liam J Murray
Journal:  J Natl Cancer Inst       Date:  2011-06-16       Impact factor: 13.506

4.  Carcinogenesis of Barrett's esophagus: a review of the clinical literature.

Authors:  Jiro Watari; Tadayuki Oshima; Hirokazu Fukui; Toshihiko Tomita; Hiroto Miwa
Journal:  Clin J Gastroenterol       Date:  2013-08-14

5.  Do proton pump inhibitors prevent Barrett's esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis.

Authors:  Yue Chen; Chenyu Sun; Yile Wu; Xin Chen; Sujatha Kailas; Zeid Karadsheh; Guangyuan Li; Zhichun Guo; Hongru Yang; Lei Hu; Qin Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2021-02-11       Impact factor: 4.553

Review 6.  Risk factors for rising incidence of esophageal and gastric cardia adenocarcinoma.

Authors:  Jacquelyn S Carr; Syed F Zafar; Nabil Saba; Fadlo R Khuri; Bassel F El-Rayes
Journal:  J Gastrointest Cancer       Date:  2013-06

7.  Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus.

Authors:  Reem Z Sharaiha; Daniel E Freedberg; Julian A Abrams; Y Claire Wang
Journal:  Dig Dis Sci       Date:  2014-05-03       Impact factor: 3.199

Review 8.  Barrett's oesophagus: frequency and prediction of dysplasia and cancer.

Authors:  Gary W Falk
Journal:  Best Pract Res Clin Gastroenterol       Date:  2015-01-20       Impact factor: 3.043

9.  Different redox states in malignant and nonmalignant esophageal epithelial cells and differential cytotoxic responses to bile acid and honokiol.

Authors:  Gang Chen; Julie Izzo; Yusuke Demizu; Feng Wang; Sushovan Guha; Xifeng Wu; Mein-Chie Hung; Jaffer A Ajani; Peng Huang
Journal:  Antioxid Redox Signal       Date:  2009-05       Impact factor: 8.401

10.  A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome.

Authors:  Michael Lanuti; Geoffrey Liu; Jonathan M Goodwin; Rihong Zhai; Bryan C Fuchs; Kofi Asomaning; Li Su; Norman S Nishioka; Kenneth K Tanabe; David C Christiani
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.